X

Clinical Trials

Contact Us

Rare Tumor

NCI 10231 (MBMC only)

NCORP Tissue Procurement Protocol: An NCI Cancer Moonshot Study


A031702 (Penile Cohort Suspended 3/13/20/ Miscellaneous GU Tract Variants Cohort suspended 7/20/20/ Small Cell Carcinoma of the Bladder Cohort Suspended 10/14/20/ Adenocarcinoma of the Bladder Cohort Closed 11/9/20))

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors


S1609 (NCT02834013)

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors


MATCH: EAY131 (NCT02465050)

MATCH: Molecular analysis for therapy choice. Targeted therapy directed by genetic testing in treating patients with advanced refractory solid tumors or lymphoma.